News

Clinical Trials Arena2h
Taiho’s DMD therapy misses the mark in Phase III trial
Taiho Pharmaceutical’s investigational Duchenne muscular dystrophy (DMD) therapy, pizuglanstat, has shown no benefit in a Phase III trial.
The Malaysian Reserve3h
SRPT Investors Have the Opportunity to Lead the Sarepta Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding ...
Muscular Dystrophy News4h
Households caring for DMD patients face high costs: US survey
Households incur substantial costs to accommodate Duchenne muscular dystrophy (DMD) patients, according to a survey of U.S.
TMCnet18h
NASDAQ: SRPT: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Sarepta Therapeutics, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta") ( NASDAQ: SRPT) on behalf ...
Robbins LLP Reminds Sarepta Therapeutics, Inc. Investors With Large Losses To Contact The Firm For Information About The SRPT Class Action Lawsuit
Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and ...